Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

PURPOSE Pulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, particularly distal clots, is unclear. The aim of the current study was to assess current treatment strategies and the long-term clinical outcomes of incidentally detected pulmonary embolism in patients with cancer. PATIENTS AND METHODS We conducted an international, prospective, observational cohort study between October 22, 2012, and December 31, 2017. Unselected adults with active cancer and a recent diagnosis of incidental pulmonary embolism were eligible. Outcomes were recurrent venous thromboembolism, major bleeding, and all-cause mortality during 12 months of follow-up. Outcome events were centrally adjudicated. RESULTS A total of 695 patients were included. Mean age was 66 years and 58% of patients were male. Most frequent cancer types were colorectal (21%) and lung cancer (15%). Anticoagulant therapy was initiated in 675 patients (97%), of whom 600 (89%) were treated with low-molecular-weight heparin. Recurrent venous thromboembolism occurred in 41 patients (12-month cumulative incidence, 6.0%; 95% CI, 4.4% to 8.1%), major bleeding in 39 patients (12-month cumulative incidence, 5.7%; 95% CI, 4.1% to 7.7%), and 283 patients died (12-month cumulative incidence, 43%; 95% CI, 39% to 46%). The 12-month incidence of recurrent venous thromboembolism was 6.4% in those with subsegmental pulmonary embolism compared with 6.0% in those with more proximal pulmonary embolism (subdistribution hazard ratio, 1.1; 95% CI, 0.37 to 2.9; P = .93). CONCLUSION In patients with cancer with incidental pulmonary embolism, risk of recurrent venous thromboembolism is significant despite anticoagulant treatment. Patients with subsegmental pulmonary embolism seemed to have a risk of recurrent venous thromboembolism comparable to that of patients with more proximal clots.

[1]  Jaron J. R. Chong,et al.  Rates of Overtreatment and Treatment-Related Adverse Effects Among Patients With Subsegmental Pulmonary Embolism , 2018, JAMA internal medicine.

[2]  M. Di Nisio,et al.  Incidental venous thromboembolism: is anticoagulation indicated? , 2017, Hematology. American Society of Hematology. Education Program.

[3]  Marcelo Sánchez,et al.  Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study , 2017, European Respiratory Journal.

[4]  L. Beenen,et al.  Incidental pulmonary embolism in cancer patients: Interobserver agreement on the diagnosis and extent with a focus on distal clots. , 2016, Thrombosis research.

[5]  A. Shinagare,et al.  Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  C. Zielinski,et al.  Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. , 2015, Thrombosis research.

[7]  A. Khorana,et al.  Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[8]  Steven Woloshin,et al.  When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found , 2013, BMJ.

[9]  G. Chatellier,et al.  Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case‐control study , 2012, Journal of thrombosis and haemostasis : JTH.

[10]  C. Dennie,et al.  Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism 1 , 2012, Journal of thrombosis and haemostasis : JTH.

[11]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[12]  P. Razavi,et al.  Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning , 2011, Journal of thrombosis and haemostasis : JTH.

[13]  D. Anderson,et al.  Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta‐analysis of the management outcome studies , 2010, Journal of thrombosis and haemostasis : JTH.

[14]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[15]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[16]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  Smita Patel,et al.  Pulmonary embolism: optimization of small pulmonary artery visualization at multi-detector row CT. , 2003, Radiology.

[18]  P. Boiselle,et al.  Multi-detector row spiral CT pulmonary angiography: comparison with single-detector row spiral CT. , 2001, Radiology.

[19]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[20]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .